Cheryl Zimberlin – Startup Investor Profile

Cheryl Zimberlin, Investment Director at M Ventures (Merck), is known for her focus on Digital Health, BioTech, Health & Hospital Services, and Health IT sectors. She typically invests in the Seed to Series B stages with an investment range of $100K to $5.0M and a sweet spot of $1.5M. Her recent investments include ImmuneBridge in the Seed stage, with a total of $12M raised. Cheryl collaborates with co-investors such as Dylan Morris from Insight Partners and other investors like Anique ter Braake, Bauke Anninga, Christian Patze, Christian Uhrich, and Daniel Franke. Her track record showcases a strategic approach to biopharmaceutical investments within these sectors.

Location: Amsterdam, Netherlands

Country: Netherlands

Investment Regions: EU

Investment Stages: pre-seed, seed

Website: https://www.m-ventures.com/en

AI Reasoning: M Ventures announced investment in ImmuneBridge with Cheryl Zimberlin joining the board in a press release dated April 11, 2023. From that date to the reference date used for classification, more than 12 months and less than 24 months have passed (about 31 months? Wait recalc). April 11, 2023 to Nov 1, 2025 is 2 years, 6 months, 21 days = >12 months. However classification: last known investment occurred between 12 and 6 months ago -> active; between now and Apr 11, 2023 is more than 12 months so should be low-active. But instruction: use date difference carefully. April 11, 2023 is over 30 months ago – that fits low-active. Therefore tag low-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.